Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer

被引:7
作者
Briones, Juan [1 ]
Khan, Maira [1 ]
Sidhu, Amanjot K. [1 ]
Zhang, Liying [1 ]
Smoragiewicz, Martin [1 ,2 ]
Emmenegger, Urban [1 ,2 ,3 ,4 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Div Med Oncol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Biol Sci Res Platform, Toronto, ON, Canada
[4] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
metastatic castration sensitive prostate cancer (mCSPC); docetaxel (DOC); abiraterone (AA); retrospective analysis; real-world effectiveness; THERAPY;
D O I
10.3389/fonc.2021.658331
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among mCSPC patients is highly variable, while there is a lack of predictive markers of therapeutic benefit. Furthermore, there is limited data on the comparative real-world effectiveness of adding DOC or ABI to androgen deprivation therapy (ADT). Methods We conducted a retrospective analysis of 121 mCSPC patients treated at Odette Cancer Centre (Toronto, ON, Canada) between Dec 2014 and Mar 2021 (DOC n = 79, ABI n = 42). The primary endpoint studied was progression free survival (PFS), defined as the interval from start of ADT to either (i) biochemical, radiological, or symptomatic progression, (ii) start of first-line systemic therapy for castration-resistant prostate cancer (CRPC), or (iii) death, whichever occurred first. To identify independent predictive factors for PFS in the entire cohort, a Cox proportional hazard model (stepwise selection) was applied. Overall survival (OS) was among secondary endpoints. Results After a median follow-up of 39.6 and 25.1 months in the DOC and ABI cohorts, respectively, 79.7% of men in the DOC and 40.5% in the ABI group experienced a progression event. PFS favored the ABI cohort (p = 0.0038, log-rank test), with 78.0% (95%CI 66.4-91.8%) of ABI versus 67.1% (57.5-78.3%) of DOC patients being free of progression at 12 months. In univariate analysis superior PFS was significantly related to older age at diagnosis of mCSPC, metachronous metastatic presentation, low-volume (CHAARTED), and low-risk (LATITUDE) disease, >= 90% PSA decrease at 3 months (PSA90), and PSA nadir <= 0.2 at 6 months. Age (HR = 0.955), PSA90 (HR = 0.462), and LATITUDE risk stratification (HR = 1.965) remained significantly associated with PFS in multivariable analysis. OS at 12 months was 98.7% (96.3-100%) and 92.7% (85.0-100%) in the DOC and ABI groups (p = 0.97), respectively. Conclusions In this real-world group of men undergoing treatment intensification with DOC or ABI for mCSPC, we did not find a significant difference in OS, but PFS was favoring ABI. Age at diagnosis of mCSPC, PSA90 at 3 months and LATITUDE risk classification are predictive factors of PFS in men with mCSPC.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study
    Marshall, Esaie M.
    Bertaut, Aurelie
    Desmoulins, Isabelle
    Darut-Jouve, Ariane
    Ponnelle, Tibor
    Poillot, Marie-Laure
    Beltjens, Francoise
    Arveux, Patrick
    BREAST JOURNAL, 2017, 23 (02) : 138 - 145
  • [42] Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia
    Peacock, Michael
    Quirt, Jill
    Morris, James
    So, Alan
    Sing, Charmaine Kim
    Pickles, Tom
    Tyldesley, Scott
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (11-12): : 409 - 413
  • [43] Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
    Moller, Christina Tanem
    Tafjord, Gunnar
    Blindheim, Augun
    Berge, Viktor
    Fossa, Sophie
    Andreassen, Bettina Kulle
    SCANDINAVIAN JOURNAL OF UROLOGY, 2023, 58 (01) : 101 - 108
  • [44] Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort
    Komura, Kazumasa
    Fujiwara, Yuya
    Uchimoto, Taizo
    Saito, Kenkichi
    Tanda, Naoki
    Matsunaga, Tomohisa
    Ichihashi, Atsushi
    Tsutsumi, Takeshi
    Tsujino, Takuya
    Yoshikawa, Yuki
    Nishimoto, Yudai
    Takai, Tomoaki
    Minami, Koichiro
    Taniguchi, Kohei
    Tanaka, Tomohito
    Uehara, Hirofumi
    Hirano, Hajime
    Nomi, Hayahito
    Ibuki, Naokazu
    Takahara, Kiyoshi
    Inamoto, Teruo
    Azuma, Haruhito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)
  • [45] Interaction Between Primary Tumor Resection, Primary Tumor Location, and Survival in Synchronous Metastatic Colorectal Cancer A Population-Based Study
    van der Kruijssen, Dave E. W.
    Brouwer, Nelleke P. M.
    van der Kuil, Auke J. S.
    Verhoeven, Rob H. A.
    Elias, Sjoerd G.
    Vink, Geraldine R.
    Punt, Cornelis J. A.
    de Wilt, Johannes H. W.
    Koopman, Miriam
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (07): : 315 - 324
  • [46] Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018)
    Rasouli, Mohammad Aziz
    Moradi, Ghobad
    Zareie, Bushra
    Sofimajidpour, Heshmatollah
    Tozandehjani, Sima
    Zafari, Hedyeh
    Gholami, Fatemeh
    Shahsavari, Sonia
    Hassani, Parisa
    Mohammadian, Mahshid
    BMC CANCER, 2021, 21 (01)
  • [47] Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands
    Ruiterkamp, J.
    Ernst, M. F.
    de Munck, L.
    van der Heiden-van der Loo, M.
    Bastiaannet, E.
    van de Poll-Franse, L. V.
    Bosscha, K.
    Tjan-Heijnen, V. C. G.
    Voogd, A. C.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (02) : 495 - 503
  • [48] Gleason score, surgical and distant metastasis are associated with cancer-specific survival and overall survival in middle aged high-risk prostate cancer: A population-based study
    Cao, Guangbiao
    Li, Yan
    Wang, Jinkui
    Wu, Xin
    Zhang, Zhaoxia
    Zhanghuang, Chenghao
    Han, Keqiang
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [49] Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    Fizazi, Karim
    Scher, Howard I.
    Molina, Arturo
    Logothetis, Christopher J.
    Chi, Kim N.
    Jones, Robert J.
    Staffurth, John N.
    North, Scott
    Vogelzang, Nicholas J.
    Saad, Fred
    Mainwaring, Paul
    Harland, Stephen
    Goodman, Oscar B., Jr.
    Sternberg, Cora N.
    Li, Jin Hui
    Kheoh, Thian
    Haqq, Christopher M.
    de Bono, Johann S.
    LANCET ONCOLOGY, 2012, 13 (10) : 983 - 992
  • [50] Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: A population-based study
    Sun, Zewen
    Sui, Xizhao
    Yang, Fan
    Wang, Jun
    LUNG CANCER, 2019, 129 : 98 - 106